This slide show features a CT image, and pathology images of gastrointestinal stromal tumors (GISTs) arising in the stomach using H&E, CD34, and c-Kit staining.
Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC
As a single agent or in combination, MK-1084 showed promising efficacy and safety results for patients with KRAS G12C–mutated CRC.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC
The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.
Educating Patients and Clinicians on End-of-Life Care and Discussions
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
ctDNA-Informed Treatment Doesn’t Impact RFS in Stage III Colon Cancer
Escalated adjuvant chemotherapy did not improve recurrence-free survival in patients with stage III colon cancer when using a ctDNA-informed approach.
T-DXd Emerges as New Standard of Care for Second-Line HER2+ Gastric/GEJ Cancer
T-DXd improved OS, PFS, ORR, and DOR vs ramucirumab plus paclitaxel in the second-line treatment of HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.